Johnson & JohnsonvsPfizer

JNJ and PFE stock compared: price, dividend, valuation and results, from SEC filings.

Johnson & Johnson (JNJ) has a market value of $672B and Pfizer (PFE) $162B. Over the last year, with dividends, JNJ moved +45.4% and PFE +21.3%. The P/E is 41.7 for JNJ and 40.1 for PFE. Dividend yield: JNJ 1.89%, PFE 6.04%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$672B

    PFE$162B

    JNJ is 4.1 times PFE

  • Revenue, 12 months

    JNJ$99.3B

    PFE$63.6B

    JNJ is 1.6 times PFE

  • Net income, 12 months

    JNJ$16.1B

    PFE$4.0B

    JNJ is 4.0 times PFE

  • Operating margin

    JNJ–

    PFE–

  • ROIC

    JNJ12.4%

    PFE2.2%

    10.2 points apart

  • P/E

    JNJ41.7

    PFE40.1

    About the same

  • Dividend yield

    JNJ1.9%

    PFE6.0%

    4.1 points apart

  • 5-year return

    JNJ+97.0%

    PFE-24.7%

    121.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+97.0%

PFE-24.7%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsPFEWith dividends
1 year since November 14, 2025+45.4%Price +42.2%+21.3%Price +13.6%
3 years since November 17, 2023+102.6%+26.5% a yearPrice +86.1%+15.6%+4.9% a yearPrice -4.8%
5 years since November 16, 2021+97.0%+14.5% a yearPrice +71.3%-24.7%-5.5% a yearPrice -42.6%
10 years since November 17, 2016+213.7%+12.1% a yearPrice +139.1%+49.9%+4.1% a yearPrice -5.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPFEPfizer

Valuation

JNJPFE
Valuation
Price$278.70$28.47
Market value$672B$162B
Enterprise value (EV)$699B$214B
P/E41.740.1
P/E, 5-year median21.918.3
P/B8.21.8
EV/EBIT39.450.2
Free cash flow yield3.1%7.3%

Results and growth

JNJPFE
Results and growth
Revenue, 12 months$99.3B$63.6B
Net income, 12 months$16.1B$4.0B
Free cash flow, 12 months$20.6B$11.8B
Earnings per share, 12 months$6.59$0.70
Revenue growth, year on year6.1%-1.7%
Revenue growth a year, past+2.7%over 5 years+8.5%over 5 years
EPS growth a year, past+14.9%over 5 years-3.6%over 5 years

Margins and returns on capital

JNJPFE
Margins and returns on capital
Gross margin67.6%73.4%
Operating margin––
Net margin16.2%6.3%
ROIC12.4%2.2%
ROE19.7%4.6%

Balance sheet

JNJPFE
Balance sheet
Cash$17.2B$10.9B
Total debt$44.7B$62.7B
Net debt / EBITDA1.14.8
Interest cover18.0×1.6×

Dividends and buybacks

JNJPFE
Dividends and buybacks
Dividend yield1.9%6.0%
Dividend per share, 12 months$5.28$1.72
Dividend growth a year, past+5.3%over 5 years+2.4%over 5 years
Buyback yield0.9%–
Shareholder yield2.8%6.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PFE

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Pfizer?

By market value, Johnson & Johnson ($672B) is about 4.1 times Pfizer ($162B), at today's prices.

How did JNJ and PFE stock do over the last 10 years?

Since November 17, 2016, JNJ's price moved +139.1% and PFE's -5.4%. With dividends: JNJ +213.7% (+12.1% a year), PFE +49.9% (+4.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PFE?

The dividend yield at today's price is 1.89% for Johnson & Johnson and 6.04% for Pfizer. Over the last twelve months they paid $5.28 and $1.72 per share.

What is the P/E of JNJ and PFE?

At today's price, the P/E is 41.7 for JNJ and 40.1 for PFE. The median of the last five years was 21.9 and 18.3, which shows where each stands against its own past.

Which has the higher profit margins, Johnson & Johnson or Pfizer?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 6.3% for Pfizer, and the operating margin – and –. Revenue was $99.3B and $63.6B.

Which is the better investment, Johnson & Johnson or Pfizer?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.